Biomarker Testing Navigation Community

The goal of the Biomarker Testing Navigation Community is to build a supportive, informative, and engaging community where knowledge flows freely and no one navigates biomarker testing alone. This community is open to both ASCP members and non-members

  • 1.  Foundations of Personalized Care: What Would You Say?

    Posted 10-29-2025 14:58

    Welcome to the discussion forum for BTN Module One: Foundations of Precision Medicine and Personalized Cancer Care Delivery!

    We know that talking about complex topics like biomarkers and precision medicine can feel intimidating at first, but this community is here to learn and grow together. To break the ice and apply a learning objective from our first BTN module, let's start with a practical, high-impact question.

    Your challenge:  If a friend or family member were recently diagnosed with cancer, and they asked you to briefly explain the most important reason they should be asking their oncologist about "biomarker testing," what would you tell them?

    Jump in and share your perspective!



    ------------------------------
    Lynnette Pineault, MBA, SCT (ASCP)
    Chair, Biomarker Testing Navigation Program
    Minneapolis, MN
    ------------------------------


  • 2.  RE: Foundations of Personalized Care: What Would You Say?

    Posted 10-30-2025 11:58

    Cancer tumor treatment is not a one size fits all.  It's not as easy as the doctor can just give you any medication chemo radiation and it will work.  The oncology team must first find out what type of tumor it is.  Also if there may be another type hiding within.  Biomarkers narrow down and define it.  One example is a breast tumor.  Although it's located in the breast did originate in another area of the body.  

    Secondly biomarkers can tell the doctor what treatments will attack this tumor.  The wrong type of treatment doesn't help.  If the treatment given is specific for colon cancer its not going to help with other types of cancers.

    Biomarkers are also useful in telling the doctor how well the treatment will work



    ------------------------------
    Doreen Koch Technologist/Scientist, non-supervisor (CT,MLS,MT)
    Clinton Township MI
    (586)243-2829
    ------------------------------

    Original Message


  • 3.  RE: Foundations of Personalized Care: What Would You Say?

    Posted 10-31-2025 00:06

    Absolutely true, thanks for Sharing Doreen-in addition to helping doctors identify the specific type of cancer and choose the most effective treatment, it also helps genetic counselors identify hereditary causes and risks and also provides information on the appropriateness of certain therapies.  It's a key step in personalizing care, choosing effective therapies and avoiding those that won't work for a certain tumor type or condition.



    ------------------------------
    Lynnette Pineault, MBA, SCT (ASCP)
    Chair, Biomarker Testing Navigation Program
    Minneapolis, MN
    ------------------------------

    Original Message


  • 4.  RE: Foundations of Personalized Care: What Would You Say?

    Posted 10-31-2025 14:15

    Our bodies have specific capabilities and attributes amongst ourselves. One example is the CYP enzymes in the liver and how different types of CYP can metabolize statins effectively (or ineffectively). Asking your oncology team to determine the blueprint of your genetic structure will set the stage for finding effective treatments and not waste your time and effort in suboptimal treatment plans.



    ------------------------------
    Pamela Banning Industry Professional
    Estacada OR
    (503)481-2750
    ------------------------------

    Original Message


  • 5.  RE: Foundations of Personalized Care: What Would You Say?

    Posted 30 days ago
    Edited by Joseph Kim 29 days ago

    Many patients can get confused when the discussion goes into "molecular" or "genetic" testing. Since these terms may refer to germline and/or somatic testing, it's important to explain why these tests are important, how they may inform treatment decisions, and how germline results may impact family members. 



    Original Message


  • 6.  RE: Foundations of Personalized Care: What Would You Say?

    Posted 29 days ago

    Well, My this context is for my Patients .....!
        When we say genetic or molecular testing terms, it simply means we are checking your body's instruction book and your DNA in detail. It's just like a small spelling mistake can change the whole story in a book, a tiny change in your DNA can sometimes cause illness. 
    Germline testing looks at the DNA you were born with, the one you got from your parents. If we find something here dramatic, it can sometimes help your family members too and next generation to get rid from that sort of problem that you are facing now.
    On the other hand, Somatic Testing looks only at the changes that happened inside the cancer cells. These are not inherited they just developed in the cancer with time. oif we will find these changes that only can be possible with genetic and moelcular testing, we will provide you right treatment, like which medicine will work best for your specific cancer type, stage and phase of cell. 
    So basically, these tests help us to understand story of your body what you got from your Mom and DAD. After these genetci and moelcuar tetsing, we only be able to treat you as well NEXT generation s that are coming after few decase from you guyz. We can treat you smarter and maybe protect your loved ones too.

       > Trust us,     we will try our best and bestest way to save you from this dig that you have in shae of Cancer. 



    ------------------------------
    Muhammad Haris Baig
    Asan-Si
    (010)749-81154
    ------------------------------

    Original Message


  • 7.  RE: Foundations of Personalized Care: What Would You Say?

    Posted 28 days ago
    Cancer results from DNA or chromosomal alterations.  In recent years, the medical and research communities have developed new therapies for cancer that focus on the specific damage that has occurred to a patient's DNA.  Even within a single cancer type such as breast cancer, different types of DNA damage make the cancer respond differently to traditional treatments.  Biomarker testing can reveal the specific types of DNA damage that a patient has. Oncologists can utilize this biomarker information to make treatments more specifically targeted for each patient.  These new therapies often have fewer side-effects and are more successful in treating the cancer than previous methods.

    Lisa Haley, M.S., ASCP-MB(CM) 

    Genomics Field Application Scientist-Central & Mountain States 

    Diagnostics and Genomics Group 

    Agilent Technologies, Inc. 

    T: +1 303-746-1143      www.agilent.com 

    lisa.haley@agilent.com 

     

     

     

     

     

    https://urldefense.proofpoint.com/v2/url?u=https-3A__www.surveymonkey.com_r_FSG8Q89&d=DwMFAg&c=FGzDrZ8hK6OoO1oc9Smc5l64O0n3B5aByDFzrvN9KLI&r=PJ16TYHKdmiujWUWaE-fmcsacqlqfwzwO1fClwu3Smlih4_sJVAbhm2gDILbsTs7&m=1PwzKW8S971UEDGcjkhAoHAEACTNnBQIf0HaFF5Zhwo&s=QIyzhibwrH76DMpqHRnuQS9ql33un4aYx2EsrYQIk78&e=. Click or tap if you trust this link." target="_blank" href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.surveymonkey.com_r_FSG8Q89&d=DwMFAg&c=FGzDrZ8hK6OoO1oc9Smc5l64O0n3B5aByDFzrvN9KLI&r=PJ16TYHKdmiujWUWaE-fmcsacqlqfwzwO1fClwu3Smlih4_sJVAbhm2gDILbsTs7&m=1PwzKW8S971UEDGcjkhAoHAEACTNnBQIf0HaFF5Zhwo&s=QIyzhibwrH76DMpqHRnuQS9ql33un4aYx2EsrYQIk78&e=">http://www.agilent.com/cs/promotions/images/Agilent_Logo_Tag_v_RGB_1.33w.png 

    To reach additional technical support resources please contact: 

    SureSelect/NGS Support: ngs.support@agilent.com | 1-800-227-9770 option 3, 4, 4 

    Bioanalyzer/Tapestation Support: electrophoresis@agilent.com | 1-800-227-9770 option 3, 4, 1 

    CGH/Exp Microarray Support: genomics@agilent.com | 1-800-227-9770 option 3, 4, 2 

      

    Agilent is committed to respecting and protecting your privacy. To view the promises that we make to you regarding  

    your personal information, please view Agilent's privacy statement. For questions related to privacy, please send your  

    inquiry to privacy_advocate@agilent.com. If you prefer not to receive promotional e-mails from Agilent in the future,  

    you can unsubscribe at any time. You can also update your e-mail address, contact information, or interest profile to  

    ensure you receive the most relevant information. 

     


    e7d8e1fdbe624569a189fd5dbe7ffba1@agilent.com?anonymous&ep=bwmEmailSignature">
    e7d8e1fdbe624569a189fd5dbe7ffba1@agilent.com?anonymous&ep=bwmEmailSignature">Book time to meet with me



    Original Message


  • 8.  RE: Foundations of Personalized Care: What Would You Say?

    Posted 27 days ago

    The NCCN guidelines usually provide clear indications for testing with demonstrated clinical utility. Ask about the clinical context and the specimen source, including diagnostic tissue from a primary biopsy, cell free DNA from procedural fluids such as pleural effusions, or peripheral blood cell free DNA for measurable disease monitoring. Ask whether sequencing is tumor only or tumor and normal, since a matched normal control can distinguish somatic from germline variants. For liquid biopsy, ask whether the assay is tumor informed or tumor naive, because prior tumor genotyping influences the sensitivity and specificity of assay performance. Finally, be reassured that oncologists routinely consult with pathologists to optimize care management.



    ------------------------------
    Chandler Ho Technologist/Scientist, non-supervisor (CT,MLS,MT)
    Daly City CA
    (415)254-7239
    ------------------------------

    Original Message